IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs
The Infectious Disease Research Institute (IDRI) today announced it has received a multi-million dollar grant from the Bill and Melinda Gates Foundation for "Chemical genomics for the identification of targets and leads in tuberculosis." The purpose of the grant is to identify new leads and new drug targets suitable for further drug development, with the ultimate goal of producing new drugs to treat tuberculosis (TB). The grant is part of the Foundation's TB Drug Accelerator program.
According to the World Health Organization, nearly 2 million people die of TB each year. Approximately 9 million people are newly infected with TB annually, and half a million cases are resistant to the multiple drugs that once effectively treated the disease.
IDRI will identify and evaluate promising new drug-like compounds which are active against the human pathogen Mycobacterium tuberculosis, using medium- and high- throughput screens. The Lilly TB Drug Discovery Initiative, of which IDRI is a member, will play a critical role in the work by providing IDRI access to a library of approximately 800,000 compounds belonging to Eli Lilly and Company. IDRI will leverage its expertise in molecular and microbial biology to identify novel targets for future drug screening.
Tanya Parish, director of drug discovery at IDRI and principal investigator on the project, said, "We are extremely pleased to be given the opportunity to further our work in TB drug discovery with this grant."
"We are excited about the momentum this award provides to our TB drug discovery program," added Steve Reed, head of research and development and founder of IDRI.
Ultimately, the project will result in identifying promising compounds that can be further developed into new drugs to treat TB.
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
